Filtered By:
Source: Baylor University Medical Center Proceedings
Condition: Diabetes Mellitus
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
Abstract
In 2015, the US Food and Drug Administration (FDA) approved the anti-proprotein convertase subtilsin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, to treat patients with hypercholesterolemia and mixed dyslipidemia. Since then, considerable attention has been paid to the use of these monoclonal antibodies for the treatment of diabetic dyslipidemia with a goal of reducing the risk for cardiovascular disease. Recently, consensus statements on the clinical use of PCSK9 inhibitors in patients with type 2 diabetes mellitus, who are unable to achieve the goal of low-density lipoprotein c...
Source: Baylor University Medical Center Proceedings - April 1, 2018 Category: Universities & Medical Training Authors: Zhang J, Tecson KM, Rocha NA, McCullough PA Tags: Proc (Bayl Univ Med Cent) Source Type: research
